Podcast Episodes
Back to SearchManaging CNS Involvement in HER2+ Lung Cancer
Episode 575
Drs. Cooper and Rotow review the challenges of CNS involvement in HER2+ NSCLC, emphasizing the importance of baseline and ongoing brain imaging, and …
11 months, 1 week ago
Could a chemo-free regimen surpass the standard triplet in HER2+ Breast Cancer?
Episode 574
A New England Journal of Medicine study showed a novel chemotherapy regimen, trastuzumab deruxtecan combined with pertuzumab, outperformed the curren…
11 months, 1 week ago
Evolving Second-Line Strategies in HER2+ Lung Cancer
Episode 573
Drs. Rotow and Cooper explore the evolving landscape of HER2+ NSCLC treatment, highlighting recent advancements in targeted therapies like HER2 TKIs …
11 months, 1 week ago
First-Line Strategies in HER2+ Lung Cancer
Episode 572
Drs. Cooper and Rotow discuss first-line treatment strategies for HER2+ NSCLC, highlighting the importance of comprehensive molecular testing and eme…
11 months, 2 weeks ago
Can HER2+ Metastatic Breast Cancer Be Cured?
Episode 571
Drs. Lynce and Waks explore whether advances in HER2-targeted therapy are making metastatic HER2+ breast cancer potentially curable, highlighting lon…
11 months, 2 weeks ago
What the PATINA Trial Teaches Us About Treating HER2+ Breast Cancer
Episode 570
Drs. Waks and Lynce review the PATINA trial, which showed that adding a CDK4/6 inhibitor to HER2-targeted and endocrine therapy improved progression-…
11 months, 2 weeks ago
Could there be a long-awaited breakthrough in first-line therapy for triple-negative breast cancer?
Episode 569
New research presented at ESMO 2025 confirms that datopotamab deruxtecan significantly improves progression-free and overall survival compared with c…
11 months, 2 weeks ago
Early-Stage HER2+ Breast Cancer
Episode 568
Drs. Lynce and Waks discuss advances in early-stage HER2+ breast cancer, focusing on how targeted therapies have transformed outcomes. They explore d…
11 months, 2 weeks ago
Could the choice of diabetes medication change a patient’s cardiovascular risk?
Episode 567
A large real-world study of over 1.2 million adults with type 2 diabetes found that SGLT2 inhibitors and GLP-1 receptor agonists reduced major cardio…
11 months, 3 weeks ago
Do updated COVID vaccines protect U.S. veterans from severe outcomes?
Episode 566
Data in ~300,000 U.S. veterans show the 2024–2025 COVID-19 booster cut COVID-related ED visits (−29%), hospitalizations (−39%), and deaths (−64%) ove…
1 year ago